What Does Optifast Do?
This fee will be rebateable. I know the people who say they lost 20 lbs in a week are lying. However, they stated that further evidence on responses of circulating biomarkers to both passive and active HC in humans is needed. However, since obesity is considered a chronic life-long problem for many individuals, periodic continual follow-up is recommended. Bioelectrical impedance analysis whole body composition assessment, with interpretation and report.
Many patients come to the clinic with undiagnosed diabetes, high cholesterol, thyroid disorders, abnormal liver tests or obstructive sleep apnea. Additional testing may be recommended depending upon the medical history and physical findings.
Overall, the physician management of obesity may include:. Diet and exercise are often the front-line of defense when it comes to weight-loss, and most individuals affected by obesity do struggle with this; however, diet and exercise should be the first place for you to start. Regardless of treatment choice, lifestyle modification through diet and exercise is essential to the success of any weight-loss program.
Diet It seems simple, right? We just need to control the calories that we consume. Unfortunately, deprivation from foods we are used to eating is difficult to accept by our bodies and minds. In addition, when dieting, the body reacts very quickly by activating compensatory mechanisms that increase appetite and slow metabolism.
This makes dieting even harder. As a result, the weight-loss achieved by diet alone is about 5 percent of total body weight. With the integration of technology, you can easily log your daily caloric intake and keep track of what you eat. Physical Activity Physical activity is an important addition to diet, as it boosts metabolism and increases weight-loss.
Physical activity is particularly important in helping to maintain weight-loss long-term. There are many tools available to help you find the right exercise for you.
From smartphone apps to full-service fitness centers equipped with all the bells and whistles, you can easily make exercise a part of your daily routine. Start slow by simply going for a walk each day and build up to more intense exercises such as jogging, swimming, biking, weight lifting and more. Pre-packaged Meal Replacement Plans Pre-packaged meal replacement plans are a medically supervised weight management program that utilizes meal replacement products and behavior change counseling to help patients reach and maintain their weight-loss goals.
These programs work to help patients transition to self-prepared meals and offer patient education and support. How do they work? Individuals who are interested in starting a supervised weight management program must do so through a healthcare professional. Most programs will list participating providers in the area on their Web site. A medically supervised weight management program consists of various phases individualized to the needs of the person seeking weight-loss.
The phases include some type of a meal replacement phase to achieve initial weight-loss and eventually transitions to a phase of self-prepared foods for long term weight management.
In addition, patients have the guidance of a team of healthcare professionals, access to group or individual counseling, as well as other support options. Programs may vary slightly. Individual results will vary, but patients may lose as much as 50 pounds or more in weeks. As with any meal replacement program, there are concerns regarding the ability of participants to be able to re-adjust to eating healthy outside the program once completed.
Additionally, insurance coverage varies depending on provider; therefore, individuals interested in the program should contact their provider to understand whether all or a portion of the program fees are covered.
Individuals may consider it expensive if it is not covered by insurance. None of the obesity medications discussed in this brochure should be taken while pregnant or attempting to become pregnant.
If you have any questions regarding these medications, please contact a healthcare provider. Who Qualifies for Obesity Medications? Although everyone is hopeful for a fast and easy way to lose weight, nothing has been shown to replace a prudent, calorie-controlled diet along with behavior modification and an increase in physical activity as a cornerstone for all obesity treatments.
Other options, such as the use of weight-loss medications, can be considered if weight-loss levels out at a still unacceptable range or if medical problems are not adequately controlled.
Pharmacologic treatment of exogenous obesity should be adjunctive to caloric restriction, increased physical activity, and behavioral modification. Other than orlistat Xenical , which is approved for use in adolescents aged 12 years or older, weight reduction medications have not been proven to be safe and effective for treatment of obesity in children and adolescents. Orlistat Xenical is contraindicated in persons with chronic malabsorption syndromes and cholestasis. Belviq is contraindicated in pregnancy.
Ioannides-Demos et al stated that there is limited safety and effectiveness data for amfepramone diethylpropion and phentermine and their approvals for the management of obesity are limited to short-term use. The authors stated that, although the benefit-risk profiles of sibutramine and orlistat appear positive, sibutramine continues to be monitored because of long-term safety concerns.
The safety and effectiveness of currently approved drug therapies have not been evaluated in children and elderly patient populations. Available evidence does not support the use of whole body DEXA for managing obesity.
There is currently no established role for whole body bioimpedance for weight reduction or other indications. Nowadays, medicinal plants and natural treatments are becoming more and more popular. Diabetes has historically been treated with plants or plant-derived formulations in different cultures, mainly in China, Asia and India.
Different mechanisms for the anti-diabetic effect of plants have been proposed: The scientific evidences for most of these plants are still incomplete. The large market for plant remedies has resulted in an array of unauthorized products or marketed as dietary supplements and, at the same time, no reliable pharmaceutical-grade products are registered for this purpose.
Borel et al conducted a prospective intervention study in viscerally obese men classified according to their glucose tolerance status. The results showed insulin sensitivity improved in assocication with decreases inboth visceral VAT and subcutaneous adiposity SAT as well as improvement in CRF, regardless of baseline glucose tolerance.
The results of this study also shoed that reduction in VAT was associated with an improvement in homeostasis model assessment of insulin resistance, whereas reduction in SAT was rather associated with improvement of the insulin sensitivity index of Matsuda. Subjects were randomly assigned to placebo, 7. Mulholland et al stated that evidence from the literature supports the safe use of very-low-energy diets VLED for up to 3 months in supervised conditions for patients who fail to meet a target weight loss using a standard low-fat, reduced-energy approach.
There is, however, a need for longer-term outcomes on obesity and associated morbidities following a VLED. These researchers investigated longer-term outcomes from studies using VLED, with a minimum duration of 12 months, published between January and December Reference lists of studies and reviews were manually searched.
Weight loss or prevention of weight gain and morbidities were the main outcomes assessed. A total of 32 out of articles met the inclusion criteria. The duration of the studies ranged from 12 months to 5 years.
Periods of VLED ranged from 25 d to 9 months. Several studies incorporated aspects of behavior therapy, exercise, low-fat diets, low-carbohydrate diets or medication.
Current evidence demonstrated significant weight loss and improvements in blood pressure, waist circumference and lipid profile in the longer term following a VLED. Interpretation of the results, however, was restricted and conclusions with which to guide best practice were limited due to heterogeneity between the studies.
The authors concluded that the present review clearly identified the need for more evidence and standardized studies to assess the longer-term benefits from weight loss achieved using VLED. Clinicians supposedly can screen for abnormally low metabolic rates, teach energy balance, and identify the precise caloric intake needed for weight loss. Clinical applications of indirect calorimetry include obesity treatment, as well as treating obesity related diseases such as diabetes, dysmetabolic syndrome X, hypothyroidism, hyperthyroidism, hypertension, cardiovascular disease, as well as sleep apnea.
Under strict laboratory protocol, indirect calorimetry can also be used to measure basal metabolic rate. Published studies of indirect calorimetry in weight management have focused on its accuracy Frankenfeld, et al. Difference in weight loss between the treatment and usual care group were —4.
The investigators noted that study limitations include small sample size, short duration, and small treatment effect. An additional issue is the generalizability of the findings, given that, at the time of the study, the Air Force had regulations that all personnel maintain a desired body weight and body fat percentage, or these individuals could be discharged from service.
The investigators stated that future research is needed to determine the long-term efficacy of using indirect calorimetry as part of a comprehensive weight control program. Close to one-half of cancer patients being evaluated in an outpatient cachexia clinic are noted to be hypermetabolic by indirect calorimetry.
Whiting et al stated that capsaicinoids are a group of chemicals naturally occurring in chilli peppers with bioactive properties that may help to support weight management. These investigators conducted a meta-analysis investigating the potential effects of capsaicinoids on energy intake, clarified previous observations and formed evidence-based conclusions about possible weight management roles.
Medical databases Medline, Web of Knowledge and Scopus were systematically searched for papers. Of the 74 clinical trials identified, 10 were included, 8 of which provided results suitable to be combined in analysis participants. From the studies, 19 effect sizes were extracted and analyzed using MIX meta-analysis software.
Data analysis showed that capsaicinoid ingestion prior to a meal reduced ad libitum energy intake by Study findings suggested a minimum dose of 2 mg of capsaicinoids is needed to contribute to reductions in ad libitum energy intake, which appears to be attributed to an altered preference for carbohydrate-rich foods over foods with a higher fat content.
The authors concluded that meta-analysis findings suggested that daily consumption of capsaicinoids may contribute to weight management through reductions in energy intake. Subsequently, there may be potential for capsaicinoids to be used as long-term, natural weight-loss aids. They stated that further long-term randomized trials are now needed to investigate these effects.
In a systematic review, Onakpoya et al a evaluated the evidence for or against the effectiveness of glucomannan, a soluble fiber, in body weight reduction. Hand searches of bibliography were also conducted. Outcomes of interest were body weight and BMI. A total of 18 trials were identified, and 9 were included. There was a variation in the reporting quality of the included RCTs. A meta-analysis random effect model of 8 RCTs revealed a non-statistically significant difference in weight loss between glucomannan and placebo mean difference [MD]: Adverse events included abdominal discomfort, diarrhea, and constipation.
The authors concluded that the evidence from available RCTs does not show that glucomannan intake generates statistically significant weight loss. They stated that future trials should be more rigorous and better reported. Onakpoya et al b noted that several slimming aids being sold as food supplements are widely available. One of them is pyruvate. Its effectiveness in causing weight reduction in humans has not been fully established.
The objective of this systematic review was to examine the effectiveness of pyruvate in reducing body weight. Electronic and non-electronic searches were conducted to identify all relevant human RCTs. The bibliographies of all located articles were also searched.
No restrictions in language or time were applied. Two independent reviewers extracted the data according to predefined criteria. A total of 9 trials were identified and 6 were included. All had methodological weaknesses.
The meta-analysis revealed a statistically significant difference in body weight with pyruvate compared to placebo MD: The magnitude of the effect is small, and its clinical relevance is uncertain. Adverse events included gas, bloating, diarrhea, and increase in low-density lipoprotein LDL cholesterol.
The authors concluded that the evidence from RCTs does not convincingly show that pyruvate is effective in reducing body weight; limited evidence exists about the safety of pyruvate.
They stated that future trials involving the use of this supplement should be more rigorous and better reported. The labeling of Saxenda states that liraglutide should not be used with insulin FDA, It also states that the the effects of liraglutide on cardiovascular morbidity and mortality have not been established.
The labeling states that the safety and efficacy of coadministration with other products for weight loss have not been established. In addition, liraglutide has not been studied in patients with a history of pancreatitis. Liraglutide for chronic weight management is contraindicated in the following conditions: Trial data showed that liraglutide, in combination with a reduced-calorie diet and increased physical activity, resulted in significantly greater weight loss than diet and physical activity alone.
The SCALE phase 3 clinical trial program of the safety and effectiveness of liraglutide for chronic weight management included three clinical trials that included approximately 4, obese and overweight patients with and without significant weight-related conditions FDA, All patients received counseling regarding lifestyle modifications that consisted of a reduced-calorie diet and regular physical activity.
Results from a clinical trial that enrolled patients without diabetes showed that patients had an average weight loss of 4. In this trial, 62 percent of patients treated with liraglutide lost at least 5 percent of their body weight compared with 34 percent of patients treated with placebo. Results from another clinical trial that enrolled patients with type 2 diabetes showed that patients had an average weight loss of 3.
In this trial, 49 percent of patients treated with liraglutide lost at least 5 percent of their body weight compared with 16 percent of patients treated with placebo. The FDA approved labeling states that patients using liraglutide should be evaluated after 16 weeks to determine if the treatment is working FDA, If a patient has not lost at least 4 percent of baseline body weight, liraglutide should be discontinued, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.
Saxenda is a glucagon-like peptide-1 GLP-1 receptor agonist and should not be used in combination with any other drug belonging to this class, including Victoza, a treatment for type 2 diabetes FDA, Saxenda and Victoza contain the same active ingredient liraglutide at different doses 3 mg and 1. However, Saxenda is not indicated for the treatment of type 2 diabetes, as the safety and efficacy of Saxenda for the treatment of diabetes has not been established.
Saxenda has a boxed warning stating that thyroid C-cell tumors have been observed in rodent studies with liraglutide but that it is unknown whether liraglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma MTC , in humans FDA, Liraglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of rats and mice.
It is unknown whether liraglutide causes thyroid C-cell tumors, including MTC, in humans, as the human relevance of liraglutide-induced rodent thyroid C-cell tumors has not been determined. The labeling states that liraglutide is contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 MEN 2 FDA, The labeling states that patients should be counseled regarding the risk of MTC with use of liraglutide and informed of symptoms of thyroid tumors e.
The labeling states that routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with liraglutide. Serious side effects reported in patients treated with liraglutide for chronic weight management include pancreatitis, gallbladder disease, renal impairment, and suicidal thoughts FDA, Liraglutide can also increase heart rate and should be discontinued in patients who experience a sustained increase in resting heart rate.
Based on spontaneous postmarketing reports, acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with liraglutide Novo Nordisk, After initiation of liraglutide, patients should be observed for signs and symptoms of pancreatitis including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting.
If pancreatitis is suspected, liraglutide should promptly be discontinued and appropriate management should be initiated. If pancreatitis is confirmed, liraglutide should not be restarted. Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in liraglutide-treated patients than in placebo-treated patients even after accounting for the degree of weight loss Novo Nordisk, If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
When liraglutide is used with an insulin secretagogue e. The labeling recommends lowering the dose of the insulin secretagogue to reduce the risk of hypoglycemia. Renal impairment has been reported postmarketing, usually in association with nausea, vomiting, diarrhea, or dehydration, which may sometimes require hemodialysis Novo Nordisk, The labeling recommends using caution when initiating or escalating doses of liraglutide in patients with renal impairment.
Serious hypersensitivity reactions e. The labeling recommends that patients stop taking liraglutide and seek medical advice if symptoms of hypersensitivity reactions occur. Liraglutide should be discontinued in patients who experience suicidal thoughts or behaviors. Liraglutide should be avoided in patients with a history of suicidal attempts or active suicidal ideation. The labeling states that nursing mothers should either discontinue liraglutide for chronic weight management or discontinue nursing Novo Nordisk, I did the Optifast program along with excercise.
Like any other diet you have to stick with it. Best program I have ever done. I have been on the optifast meal replacements for about 2 weeks now and it is the hardest thing i have done up to date. I also need to lose lbs and so far i have lost 20lbs in 2 weeks. My question to you is, about how many pounds did you average to lose per week and what type of exercise did you do and are doing? It is an amazing product. I love the Vanilla Powder Shakes.
I blend it together with water, ice, powder and a sprinkle of Starbucks instant coffee. I have been on Optifast for six months. I have lost 60 pounds. I drink two shakes a day and a Lean Cuisine for dinner. In the beginning, I did three shakes and two cups of veggies. After three-four weeks, I switched to the shakes a day.
I could do this the rest of my life. Have been on Optifast for 3 weeks have only lost 5 pounds. Last week I gained 1 pound. What the hell is going on? I have followed the program with 4 products and 1 meal a day. I am on quite a bit of meds for A fib and Hypertension. Could it be that I have very painful arthritis and cannot do much activity? I am ready to quit.
It is sooo expensive not to have lost any more than 5 pounds. It should be 6 products a day and lots of water. I do have fibromyalgia problems at one time I gained 40 pounds in 4 months and years later they tried me another medication I gained 30 pounds in 3 months I had to stop at medication being so heavy was worse on my health than the fibromyalgia pain alone. I have been on the program 70 days, lost 35 pounds and have not felt this great in a long time.
The program is not cheap by any means but I have multiple medical issues, needed to lose a lot of weight, They follow my progress at least weekly and are availabe to help me if I have a problem. There is also a support group when you complete the program. This is not a program for those who want the easy way out, you also have to work exercise to achieve. Make sure you are including some benefiber-type product for bulk in your diet. Could be constipation related. Benefiber is more expensive but you can buy a house brand at CVS that is more reasonable.
Optifast is a medically supervised program. Call her doctor immediately. She could have a gallstone problem. I just started optifast yesterday. Today, after slight exertion I found myself sweating profusely and not feeling good. Prior to eating I did a fingerstick and it was , the highest its ever been fasting.
Can anyone explain why this happened? When I started Optifast my doctor warned me that my blood sugar could bounce all over the place initially since I stopped all diabetic pills when I started Optifast. I have been lucky and my blood sugars have been between 94 and Give it a little time and you should level out.
The way I look at it depends on what you spend on food for your household and how much you eat but and maybe a few dollars extra than what you spend normally but which is way worth it! How much sugar is in each shake? That would easily raise blood sugar. Especially without the added fat to slow digestion. They contain milk products and all contain about 1gm of lactose, except for the vanilla powder, which contains grams of lactose.
I just my first 2 weeks on the opti-fast So far its been 3 days, anyone finding 4 shakes a day hard? I know I am, there are so filling. Plus I have to drink tons of water. I hope the weight loss starts soon. I just did my first weigh in lost 10 lbs first week. I know the people who say they lost 20 lbs in a week are lying. I followed this to the letter. I never heard of losing twenty lbs in a week. The program is good.
You did a great job for yourself and YOUR journey. They may have more weight than you to lose. Be kind and encouraging. For more information, see our full Advertising Disclosure. Click here to find out why we're giving away samples of our product, Burn TS.
Need Help Finding a Diet? How many pounds do you want to lose? Please Select Less than 10 10 to 15 More than Please Select less than 4 times a month 1 - 2 times a week 3 or more times a week. Please Select 18 - 24 years old 25 - 34 years old 35 - 44 years old 45 - 54 years old 55 - 64 years old 65 - 74 years old 75 years or older.
How much support do you have at home? Please Select A lot A little Almost none. What makes it hard to lose weight? Please Select Eating too much at meals Comforting myself with food Unhealthy food at home Food just tastes so good Snacking Eating out.
Click here to get your sample of our powerful fat burner today. How you take Optifast products based on your individualized program. No, Optifast is not supported by a guarantee. Have you tried this product? Expensive and did not work at all Marybeth Verified User. Loved the product it works well Kathy Verified User.
Looking for nearest location Anonymous. Best program I have ever done faysha Verified User. I have not felt this great in a long time. Does the product contain wheat?